BR112014023496A2 - mutantes c-raf que conferem resistência a inibidores de raf - Google Patents

mutantes c-raf que conferem resistência a inibidores de raf

Info

Publication number
BR112014023496A2
BR112014023496A2 BR112014023496A BR112014023496A BR112014023496A2 BR 112014023496 A2 BR112014023496 A2 BR 112014023496A2 BR 112014023496 A BR112014023496 A BR 112014023496A BR 112014023496 A BR112014023496 A BR 112014023496A BR 112014023496 A2 BR112014023496 A2 BR 112014023496A2
Authority
BR
Brazil
Prior art keywords
raf
confer resistance
mutants
inhibitors
methods
Prior art date
Application number
BR112014023496A
Other languages
English (en)
Portuguese (pt)
Inventor
Emery Caroline
A Garraway Levi
Antony Rajee
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of BR112014023496A2 publication Critical patent/BR112014023496A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014023496A 2012-03-28 2013-03-07 mutantes c-raf que conferem resistência a inibidores de raf BR112014023496A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616999P 2012-03-28 2012-03-28
US201261708372P 2012-10-01 2012-10-01
PCT/US2013/029513 WO2013148100A1 (en) 2012-03-28 2013-03-07 C-raf mutants that confer resistance to raf inhibitors

Publications (1)

Publication Number Publication Date
BR112014023496A2 true BR112014023496A2 (pt) 2017-07-18

Family

ID=47892065

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014023496A BR112014023496A2 (pt) 2012-03-28 2013-03-07 mutantes c-raf que conferem resistência a inibidores de raf

Country Status (15)

Country Link
US (6) US9629839B2 (https=)
EP (3) EP3333575B1 (https=)
JP (3) JP6348898B2 (https=)
KR (1) KR20140139510A (https=)
CN (1) CN104204806B (https=)
AU (1) AU2013240483B2 (https=)
BR (1) BR112014023496A2 (https=)
CA (1) CA2864169A1 (https=)
EA (1) EA028135B1 (https=)
ES (3) ES2673070T3 (https=)
MX (1) MX351945B (https=)
PL (1) PL2831589T3 (https=)
PT (1) PT2831589T (https=)
TR (1) TR201808010T4 (https=)
WO (1) WO2013148100A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3333575B1 (en) * 2012-03-28 2020-02-26 Dana Farber Cancer Institute, Inc. C-raf mutants that confer resistance to raf inhibitors
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
KR102537840B1 (ko) 2018-07-13 2023-05-31 삼성전자 주식회사 서버 장치 및 다른 장치들의 위치 정보를 수집하는 방법
WO2020163771A1 (en) * 2019-02-08 2020-08-13 Portage Glasgow Limited Structure, manufacturing and uses of hoxd12-pde8a cell-penetrating peptides
WO2021225980A1 (en) * 2020-05-04 2021-11-11 Dna-Seq, Inc. Methods and systems for determination of an effective therapeutic regimen and drug discovery

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618670A (en) * 1988-08-26 1997-04-08 The United States Of America As Represented By The Department Of Health & Human Services Detection method for c-raf-1 genes
US20060234931A1 (en) 2003-07-17 2006-10-19 Biggs William H Iii Treatment of diseases with kinase inhibitors
WO2005012875A2 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
AU2007299080B2 (en) 2006-09-18 2013-04-18 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
CN101516376A (zh) 2006-09-18 2009-08-26 贝林格尔.英格海姆国际有限公司 用于治疗携带egfr突变的癌症的方法
EP2102362B1 (en) * 2006-11-16 2012-07-04 Mount Sinai School of Medicine of New York University Compositions and methods for detecting noonan syndrome
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
BR112012022801B8 (pt) * 2010-03-09 2019-10-29 Dana Farber Cancer Inst Inc método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
EP3333575B1 (en) * 2012-03-28 2020-02-26 Dana Farber Cancer Institute, Inc. C-raf mutants that confer resistance to raf inhibitors

Also Published As

Publication number Publication date
US12146196B2 (en) 2024-11-19
AU2013240483B2 (en) 2018-07-26
US20210388325A1 (en) 2021-12-16
US20170204383A1 (en) 2017-07-20
US20240093310A1 (en) 2024-03-21
KR20140139510A (ko) 2014-12-05
EP2831589A1 (en) 2015-02-04
CN104204806B (zh) 2016-02-03
JP6348898B2 (ja) 2018-06-27
US20190142830A1 (en) 2019-05-16
US9629839B2 (en) 2017-04-25
EP3333575A1 (en) 2018-06-13
EA201491780A1 (ru) 2015-01-30
US11788151B2 (en) 2023-10-17
ES2673070T3 (es) 2018-06-19
EP3693741B1 (en) 2022-01-05
CA2864169A1 (en) 2013-10-03
TR201808010T4 (tr) 2018-06-21
JP6661685B2 (ja) 2020-03-11
AU2013240483A1 (en) 2014-08-28
PT2831589T (pt) 2018-06-20
WO2013148100A1 (en) 2013-10-03
JP2020103291A (ja) 2020-07-09
EP3333575B1 (en) 2020-02-26
CN104204806A (zh) 2014-12-10
EP3693741A1 (en) 2020-08-12
JP2015513901A (ja) 2015-05-18
MX2014011686A (es) 2015-06-04
MX351945B (es) 2017-11-03
EA028135B1 (ru) 2017-10-31
ES2908078T3 (es) 2022-04-27
US20150133478A1 (en) 2015-05-14
US20250034652A1 (en) 2025-01-30
ES2790896T3 (es) 2020-10-29
PL2831589T3 (pl) 2018-10-31
EP2831589B1 (en) 2018-04-18
JP2018110594A (ja) 2018-07-19

Similar Documents

Publication Publication Date Title
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
EA201290883A1 (ru) Способы диагностики и лечения рака у пациентов, у которых имеется или развивается резистентность к первой терапии рака
MX2017014381A (es) Metodos terapeuticos y diagnosticos para cancer.
MX2016008667A (es) Inmunoglobulina con fab en tandem y usos de esta.
MX2020006151A (es) Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
EA201792642A1 (ru) Способы диагностики для т-клеточной терапии
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
MX394103B (es) Anticuerpos anti-angptl8 y usos de estos.
BR112016024352A2 (pt) ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria?
MX2021006893A (es) Acidos nucleicos libres de celulas para el analisis del microbioma humano y componentes del mismo.
BR112014023162A8 (pt) compostos e métodos para modulação quinase e indicações dos mesmos
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
MX385872B (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer
EA202090683A3 (ru) Способы и композиции для лечения рака
MX2017011486A (es) Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
EA201291206A1 (ru) Мутация в mek1, придающая устойчивость к ингибиторам raf и mek
BR112015013349A2 (pt) trieptanoína para o tratamento de deficiência de transportador de glicose 1
MY173162A (en) Immune balance regulator
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
UA117556C2 (uk) Спосіб збільшення ефективності терапевтичного засобу шляхом введення метотрексату
MX382077B (es) Polimeros de union a protones para administracion oral.
NZ601606A (en) Identification, assessment, and therapy of cancers with innate or acquired resistance to alk inhibitors
BR112014027905A2 (pt) anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico.
EP4574207A3 (en) Means and methods for treating copper-related diseases

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2621 DE 30/03/2021.